Mar 25 |
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
|
Mar 19 |
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
Mar 17 |
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
|
Mar 13 |
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
|
Mar 13 |
Poseida spikes after FDA orphan status for CAR-T therapy
|
Mar 11 |
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
|
Mar 10 |
US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results
|
Mar 9 |
Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Mar 8 |
Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 7 |
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
|